These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31830620)

  • 1. Therapeutic drug monitoring and safety of voriconazole in elderly patients.
    Cheng L; Xiang R; Liu F; Li Y; Chen H; Yao P; Sun F; Xia P
    Int Immunopharmacol; 2020 Jan; 78():106078. PubMed ID: 31830620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole.
    Vreugdenhil B; van der Velden WJFM; Feuth T; Kox M; Pickkers P; van de Veerdonk FL; Blijlevens NMA; Brüggemann RJM
    Br J Clin Pharmacol; 2018 Sep; 84(9):1980-1988. PubMed ID: 29744898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation is associated with voriconazole trough concentrations.
    van Wanrooy MJ; Span LF; Rodgers MG; van den Heuvel ER; Uges DR; van der Werf TS; Kosterink JG; Alffenaar JW
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7098-101. PubMed ID: 25223994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Adverse Events and Determinants of the Voriconazole Trough Concentration in Kidney Transplantation Recipients.
    Zhao YC; Lin XB; Zhang BK; Xiao YW; Xu P; Wang F; Xiang DX; Xie XB; Peng FH; Yan M
    Clin Transl Sci; 2021 Mar; 14(2):702-711. PubMed ID: 33202102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults.
    Mangal N; Hamadeh IS; Arwood MJ; Cavallari LH; Samant TS; Klinker KP; Bulitta J; Schmidt S
    Clin Pharmacol Ther; 2018 Nov; 104(5):957-965. PubMed ID: 29315506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment.
    Kim SH; Kwon JC; Park C; Han S; Yim DS; Choi JK; Cho SY; Lee HJ; Park SH; Choi SM; Choi JH; Yoo JH; Lee DG; Lee JW
    Mycoses; 2016 Oct; 59(10):644-51. PubMed ID: 27324913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Observational Study of Associations between Voriconazole Therapeutic Drug Monitoring, Toxicity, and Outcome in Liver Transplant Patients.
    Hashemizadeh Z; Badiee P; Malekhoseini SA; Raeisi Shahraki H; Geramizadeh B; Montaseri H
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Gender and Age on Voriconazole Trough Concentrations in Italian Adult Patients.
    Allegra S; De Francia S; De Nicolò A; Cusato J; Avataneo V; Manca A; Antonucci M; D'Avolio A
    Eur J Drug Metab Pharmacokinet; 2020 Jun; 45(3):405-412. PubMed ID: 31965553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
    Howard A; Hoffman J; Sheth A
    Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective, multicenter study of voriconazole trough concentrations and safety in patients with Child-Pugh class C cirrhosis.
    Wang T; Yan M; Tang D; Xue L; Zhang T; Dong Y; Zhu L; Wang X; Dong Y
    J Clin Pharm Ther; 2018 Dec; 43(6):849-854. PubMed ID: 29893015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Drug Monitoring of Voriconazole in Children from a Tertiary Care Center in China.
    Hu L; Dai TT; Zou L; Li TM; Ding XS; Yin T
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30150475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Voriconazole trough concentration and hepatotoxicity in patients with low serum albumin
.
    Hirata A; Noto K; Ota R; Yokoyama S; Hosomi K; Takada M; Matsuoka H
    Int J Clin Pharmacol Ther; 2019 Mar; 57(3):135-143. PubMed ID: 30686290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of inflammation on voriconazole trough concentrations in children.
    Ter Avest M; Veringa A; van den Heuvel ER; Kosterink JG; Schölvinck EH; Tissing WJ; Alffenaar JC
    Br J Clin Pharmacol; 2017 Mar; 83(3):678-680. PubMed ID: 27862167
    [No Abstract]   [Full Text] [Related]  

  • 14. An Optimized Voriconazole Dosing Strategy to Achieve Therapeutic Serum Concentrations in Children Younger than 2 Years Old.
    Zembles TN; Thompson NE; Havens PL; Kaufman BA; Huppler AR
    Pharmacotherapy; 2016 Oct; 36(10):1102-1108. PubMed ID: 27548272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic drug monitoring of voriconazole helps to decrease the percentage of patients with off-target trough serum levels.
    Guinea J; Escribano P; Marcos-Zambrano LJ; Peláez T; Kestler M; Muñoz P; Vena A; López-Fabal F; Bouza E
    Med Mycol; 2016 May; 54(4):353-60. PubMed ID: 26739190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
    Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH
    Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
    Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
    Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic administration of voriconazole with two different doses for invasive fungal infection in children and adolescents with acute myeloid leukemia.
    Sano H; Kobayashi R; Hori D; Kishimoto K; Suzuki D; Yasuda K; Kobayashi K
    J Microbiol Immunol Infect; 2018 Apr; 51(2):260-266. PubMed ID: 27329132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
    Hamadeh IS; Klinker KP; Borgert SJ; Richards AI; Li W; Mangal N; Hiemenz JW; Schmidt S; Langaee TY; Peloquin CA; Johnson JA; Cavallari LH
    Pharmacogenet Genomics; 2017 May; 27(5):190-196. PubMed ID: 28306618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients.
    Lin XB; Li ZW; Yan M; Zhang BK; Liang W; Wang F; Xu P; Xiang DX; Xie XB; Yu SJ; Lan GB; Peng FH
    Br J Clin Pharmacol; 2018 Jul; 84(7):1587-1597. PubMed ID: 29607533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.